Companies · Pharma
Davis · CA, USA · Pharma · founded 2021 · https://matrubials.com/
Diligence memoA one-page analyst read on Matrubials — recommendation, valuation, rhythm, risks.→Matrubials: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Matrubials is one of 310 Pharma companies tracked from Davis, CA, USA, on record since 2021. By capital raised it ranks in the long tail (ahead of 16% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Developing milk-inspired therapeutics for infectious diseases
Matrubials is an anti-infectives company, focused on human milk peptides as therapeutics to address antimicrobial resistance and modern diseases. Currently the global rise in severe bacterial infections and the drying pipeline of effective treatments are burdensome for healthcare and economics. Sculpted by evolution, milk, first food for the newborn, provides an exemplary solution to address the nutritive and protective challenges an infant is faced with. The anti-pathogenic molecules from milk can be developed into therapeutics geared towards all-age diseases. Our first indication is bacterial vaginosis, a bacterial dysbiosis related inflammation that results in recurrent infections, disruption of homeostasis and long-term clinical complications in women of reproductive age, including but not limited to preterm births, fertility issues and increased rates of STDs. Our next inflection point is the evaluation of rapidly acting and selective candidate peptides in pre-clinical host impact and early safety studies, which can aid clinical and portfolio development towards topical applications.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 16% of sector peers (real $). Modeled value above 16% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Matrubials is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 1200 Pharma LLC | Pharma | Series A | $14.1M | $13.2M | same sector |
| A28 Therapeutics, Inc. | Pharma | Seed | $1.9M | $31.6M | same sector |
| AbInitio Bio | Pharma | — | — | — | same sector |
| Acanna Therapeutics, Inc. | Pharma | Pre-Seed | $1.0M | $16.0M | same sector |
| Advanced Cardiac Therapeutics Inc | Pharma | Series C | $64.1M | $1.6B | same sector |
| ADvantage Therapeutics, Inc. | Pharma | Series A | $19.0M | $111.2M | same sector |
| AeroRx Therapeutics, Inc. | Pharma | Series A | $10.4M | $30.7M | same sector |
| Affect Therapeutics, Inc. | Pharma | Series B | $24.6M | $232.4M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Evolvere BioSciences Making Next-Generation Antibiotics that Outpace Bacterial Evolution | Biotech | — | — | 73% |
| Promakhos Therapeutics Inc. A therapeutics platform for curing inflammatory disorders | Biotechnology | Seed | $67.8M | 73% |
| Mati Therapeutics Inc. | Biotechnology | Series A | $28.3M | 73% |
| ImmunityBio, Inc. We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products. | Biotechnology | Growth/Late | $7.8B | 72% |
| Microbion Corp | Pharmaceuticals | Series B | $328.6M | 72% |
| Nabla Bio We use AI to design antibodies for intractable diseases | Biotech | — | — | 72% |
| SFA Therapeutics Regulating the immune system to block cancer & autoimmune diseases | Biotech | — | — | 72% |
| ImmunoMolecular Therapeutics, Inc. | Biotechnology | Series A | $215.5M | 72% |
See where Matrubials sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Matrubials, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.